Cargando…
Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study
Patients with end-stage kidney disease (ESKD) are at increased risk for SARS-CoV-2 infection and its complications compared with the general population. Several studies evaluated the effectiveness of COVID-19 vaccines in the dialysis population but showed mixed results. The aim of this study was to...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863461/ https://www.ncbi.nlm.nih.gov/pubmed/36679894 http://dx.doi.org/10.3390/vaccines11010049 |
_version_ | 1784875340146933760 |
---|---|
author | Alkadi, Mohamad M. Hamad, Abdullah Ghazouani, Hafedh Elshirbeny, Mostafa Ali, Mohamed Y. Ghonimi, Tarek Ibrahim, Rania Abuhelaiqa, Essa Abou-Samra, Abdul Badi Al-Malki, Hassan Butt, Adeel A. |
author_facet | Alkadi, Mohamad M. Hamad, Abdullah Ghazouani, Hafedh Elshirbeny, Mostafa Ali, Mohamed Y. Ghonimi, Tarek Ibrahim, Rania Abuhelaiqa, Essa Abou-Samra, Abdul Badi Al-Malki, Hassan Butt, Adeel A. |
author_sort | Alkadi, Mohamad M. |
collection | PubMed |
description | Patients with end-stage kidney disease (ESKD) are at increased risk for SARS-CoV-2 infection and its complications compared with the general population. Several studies evaluated the effectiveness of COVID-19 vaccines in the dialysis population but showed mixed results. The aim of this study was to determine the effectiveness of COVID-19 mRNA vaccines against confirmed SARS-CoV-2 infection in hemodialysis (HD) patients in the State of Qatar. We included all adult ESKD patients on chronic HD who had at least one SARS-CoV-2 PCR test done after the introduction of the COVID-19 mRNA vaccines on 24 December 2020. Vaccinated patients who were only tested before receiving any dose of their COVID-19 vaccine or within 14 days after receiving the first vaccine dose were excluded from the study. We used a test-negative case–control design to determine the effectiveness of the COVID-19 vaccination. Sixty-eight patients had positive SARS-CoV-2 PCR tests (cases), while 714 patients had negative tests (controls). Ninety-one percent of patients received the COVID-19 mRNA vaccine. Compared with the controls, the cases were more likely to be older (62 ± 14 vs. 57 ± 15, p = 0.02), on dialysis for more than one year (84% vs. 72%, p = 0.03), unvaccinated (46% vs. 5%, p < 0.0001), and symptomatic (54% vs. 21%, p < 0.0001). The effectiveness of receiving two doses of COVID-19 mRNA vaccines against confirmed SARS-CoV-2 infection was 94.7% (95% CI: 89.9–97.2) in our HD population. The findings of this study support the importance of using the COVID-19 mRNA vaccine in chronic HD patients to prevent SARS-CoV-2 infection in such a high-risk population. |
format | Online Article Text |
id | pubmed-9863461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98634612023-01-22 Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study Alkadi, Mohamad M. Hamad, Abdullah Ghazouani, Hafedh Elshirbeny, Mostafa Ali, Mohamed Y. Ghonimi, Tarek Ibrahim, Rania Abuhelaiqa, Essa Abou-Samra, Abdul Badi Al-Malki, Hassan Butt, Adeel A. Vaccines (Basel) Communication Patients with end-stage kidney disease (ESKD) are at increased risk for SARS-CoV-2 infection and its complications compared with the general population. Several studies evaluated the effectiveness of COVID-19 vaccines in the dialysis population but showed mixed results. The aim of this study was to determine the effectiveness of COVID-19 mRNA vaccines against confirmed SARS-CoV-2 infection in hemodialysis (HD) patients in the State of Qatar. We included all adult ESKD patients on chronic HD who had at least one SARS-CoV-2 PCR test done after the introduction of the COVID-19 mRNA vaccines on 24 December 2020. Vaccinated patients who were only tested before receiving any dose of their COVID-19 vaccine or within 14 days after receiving the first vaccine dose were excluded from the study. We used a test-negative case–control design to determine the effectiveness of the COVID-19 vaccination. Sixty-eight patients had positive SARS-CoV-2 PCR tests (cases), while 714 patients had negative tests (controls). Ninety-one percent of patients received the COVID-19 mRNA vaccine. Compared with the controls, the cases were more likely to be older (62 ± 14 vs. 57 ± 15, p = 0.02), on dialysis for more than one year (84% vs. 72%, p = 0.03), unvaccinated (46% vs. 5%, p < 0.0001), and symptomatic (54% vs. 21%, p < 0.0001). The effectiveness of receiving two doses of COVID-19 mRNA vaccines against confirmed SARS-CoV-2 infection was 94.7% (95% CI: 89.9–97.2) in our HD population. The findings of this study support the importance of using the COVID-19 mRNA vaccine in chronic HD patients to prevent SARS-CoV-2 infection in such a high-risk population. MDPI 2022-12-26 /pmc/articles/PMC9863461/ /pubmed/36679894 http://dx.doi.org/10.3390/vaccines11010049 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Alkadi, Mohamad M. Hamad, Abdullah Ghazouani, Hafedh Elshirbeny, Mostafa Ali, Mohamed Y. Ghonimi, Tarek Ibrahim, Rania Abuhelaiqa, Essa Abou-Samra, Abdul Badi Al-Malki, Hassan Butt, Adeel A. Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study |
title | Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study |
title_full | Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study |
title_fullStr | Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study |
title_full_unstemmed | Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study |
title_short | Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Case–Control Study |
title_sort | effectiveness of messenger rna vaccines against sars-cov-2 infection in hemodialysis patients: a case–control study |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863461/ https://www.ncbi.nlm.nih.gov/pubmed/36679894 http://dx.doi.org/10.3390/vaccines11010049 |
work_keys_str_mv | AT alkadimohamadm effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT hamadabdullah effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT ghazouanihafedh effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT elshirbenymostafa effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT alimohamedy effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT ghonimitarek effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT ibrahimrania effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT abuhelaiqaessa effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT abousamraabdulbadi effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT almalkihassan effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy AT buttadeela effectivenessofmessengerrnavaccinesagainstsarscov2infectioninhemodialysispatientsacasecontrolstudy |